Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Oct;81(4):1009-1011.
doi: 10.1016/j.jaad.2019.01.077. Epub 2019 Feb 5.

Incidence and risk of developing photosensitivity with targeted anticancer therapies

Kathryn T Ciccolini  1 , Joseph Kim  2 , Soham P Chaudhari  3 , Anna Skripnik Lucas  1 , Benjamin Benhuri  4 , Juanita Duran  5 , Shenhong Wu  6 , Mario E Lacouture  7
Affiliations
Review

Incidence and risk of developing photosensitivity with targeted anticancer therapies

Kathryn T Ciccolini et al. J Am Acad Dermatol. 2019 Oct.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest: Dr Lacouture is a consultant and speaker for Legacy Healthcare Services, Adgero Bio Pharmaceuticals, Amryt Pharmaceuticals, Celldex Therapeutics, Debiopharm, Galderma Research and Development, Johnson and Johnson, Novocure Inc, Lindi, Merck Sharp and Dohme Corporation, Helsinn Healthcare SA, Janssen Research & Development LLC, Menlo Therapeutics, Novartis Pharmaceuticals Corporation, F. Hoffmann-La Roche AG, AbbVie Inc, Boehringer Ingelheim Pharma Gmbh & Co. KG, Allergan Inc, Amgen Inc, E.R. Squibb & Sons LLC, EMD Serono Inc, Astrazeneca Pharmaceuticals LP, Genentech Inc, Leo Pharma Inc, Seattle Genetics, Bayer, Manner SAS, Lutris, Pierre Fabre, Paxman Coolers, Adjucare, Dignitana, Biotechspert, Teva Mexico, Parexel, OnQuality Pharmaceuticals Ltd, Novartis, and Our Brain Bank. Dr Lacouture also receives research funding from Berg, Bristol-Myers Squibb, Lutris, Paxman, Novocure, US Biotest, and Veloce. Dr Lacouture received royalties as a consultant for Takeda Milledium. Ms Ciccolini, Mr Kim, Dr Chaudhari, Dr Lucas, Dr Benhuri, Dr Duran, and Dr Wu have no conflicts of interest to disclose.

Figures

Fig 1.
Fig 1.
Summary of literature search and reasons for trial exclusion.
Fig 2.
Fig 2.
Relative risk for all-grade photosensitivity. To assess the specific contribution on the development of photosensitivity, we determined relative risk of these agents in comparison to controls. CI, Confidence interval; N, nivolumab; Va, vandetanib; Vem, vemurafenib.
See this image and copyright information in PMC

References

    1. Robert C, Karaszewska B, Schachter J, et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. New Engl J Med. 2015b;372:30–39. - PubMed
    1. Robert C, Long G, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. New Engl J Med. 2015a;372:320–330. - PubMed
    1. Sosman JA, Kim KB, Schuchter L, et al. Survival in BRAF V600emutant advanced melanoma treated with vemurafenib. New Engl J Med. 2012;366:707–714. - PMC - PubMed
    1. Leboulleux S, Bastholt L, Krause T, et al. Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial. Lancet Oncol. 2012;13:897–905. - PubMed
    1. Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. New Engl J Med. 2011;364:2507–2516. - PMC - PubMed

MeSH terms